Lineage Cell Therapeutics said its OpRegen regenerative vision therapy was featured at ARVO 2026’s Eyecelerator, giving the program exposure at a major ophthalm

Lineage Cell Therapeutics said its OpRegen regenerative vision therapy was featured at ARVO 2026’s Eyecelerator, giving the program exposure at a major ophthalmology forum. The therapy was discussed on a panel about prospects for vision improvement in regenerative medicine.